



Prescriber Signature: _

Remicade (Infliximab) Patient Referral and Prescription Sheet

Patient Information								
Patient Name:					Date:			
DOB:					Height:	Height:		cm
Allergies:					Weight:	Weight: ☐ lbs ☐ kg		
Primary Diagnosis								
Diagnosis ICD-10 Diagnosis ICD-10								
☐ Crohn's Disease o	of small intestine v	without complication	s K50.00	☐ Crohn's Disease of large intestine without complications K50.10			K50.10	
☐ Crohn's Disease,	unspecified witho	ut complications	K50.90	☐ Ulcerative Chronic pancolitis without complications K51.00				K51.00
☐ Plaque Psoriasis		L40.0	☐ Psoriatic Psoriasis L40.52				L40.52	
☐ Rheumatoid arth		M06.9	☐ Ankylosing Spondylitis M45.9				M45.9	
☐ Ulcerative Colitis	out complications	K51.90	□ Other					
Medication Order								
☐ Remicade	☐ Renflexis	☐ Avsola	☐ Infliximab	☐ Inflectra	☐ Zymfentra	☐ Refills x one year		
Dosing: ☐ Initiation: Administer mg/kg IV over at least two hours at weeks 0, 2 and 6 per protocol ☐ Maintenance: Administer mg/kg IV over minutes every weeks ☐ Round to the nearest 100mg vial size OR exact dose of: mg ☐ 120mg SC every 2 weeks ☐ Other							ature unless cated below	
Other Nursing Orders								
					ment for ongoing nursing mplanted VAD when info			ess and
			Ancillar	y Orders				
Pre-medications: ☐ Diphenhydramine: 25mg PO 30 min pre-infusion ☐ Acetaminophen: 650mg PO 30 min pre-infusion ☐ Famotidine: 20 mg PO x1 dose ☐ Other pre-meds: ☐ Refill x one year				IV Flush Orders: □ Peripheral: NS 1-3 mL before/after use □ Implanted VAD: NS 5 to 10 mL before/after use and 10 mL postlab draw. Heparin (100 unit/mL) 3 to 5 mL final flush □ CVAD: NS 5 to 10 mL before/after use and 10 mL postlab draw Heparin (10 units/mL) 3 to 5 mL final flush □ Refill x one year				
		e Auto-Injector dual vent of anaphylaxis.		-	_			
Therapy Specific Documentation				Other Required Documentation				
Please include the following lab results CMP CBC LFTs CRP Infliximab Trough Levels Other				□ Patient Demographics − include insurance information. We will obtain authorization unless the insurance dictates otherwise. □ H & P OR progress note(s) □ Medication List- Please list past and present DMARDS/biologics below with dates of discontinue, if applicable □ Hepatitis B Surface Antigen □ Hepatitis B Core Antibody Total (not Core IgM) □ QuantiFERON-TB Gold				
□ CMP □ CBC □ LFTs □ CRP □ Infliximab Trough				☐ H & P OR prog ☐ Medication Li with dates of ☐ Hepatitis B Su ☐ Hepatitis B Co	gress note(s) st- Please list past and p discontinue, if applicabl irface Antigen ore Antibody Total (not C	resent D e	MARDS/biolog	
□ CMP □ CBC □ LFTs □ CRP □ Infliximab Trough			Provider I	☐ H & P OR prog ☐ Medication Li. with dates of ☐ Hepatitis B Su ☐ Hepatitis B Co ☐ QuantiFERON	gress note(s) st- Please list past and p discontinue, if applicabl irface Antigen ore Antibody Total (not C	resent D e	MARDS/biolog	
□ CMP □ CBC □ LFTs □ CRP □ Infliximab Trough			Provider Ir	☐ H & P OR prog ☐ Medication Li. with dates of ☐ Hepatitis B Su ☐ Hepatitis B Co ☐ QuantiFERON	gress note(s) st- Please list past and p discontinue, if applicabl irface Antigen ore Antibody Total (not C	resent D e	MARDS/biolog	
□ CMP □ CBC □ LFTs □ CRP □ Infliximab Trough			Provider Ir	☐ H & P OR prog ☐ Medication Li with dates of ☐ Hepatitis B Su ☐ Hepatitis B Co ☐ QuantiFERON Information Program Pr	gress note(s) st- Please list past and p discontinue, if applicabl urface Antigen ore Antibody Total (not C -TB Gold	resent D e	MARDS/biolog	
□ CMP □ CBC □ LFTs □ CRP □ Infliximab Trough □ Other □ Provider Name:			Provider Ir	☐ H & P OR prog ☐ Medication Li with dates of ☐ Hepatitis B Su ☐ Hepatitis B Co ☐ QuantiFERON Information Program Pr	gress note(s) st- Please list past and p discontinue, if applicable ore Antigen ore Antibody Total (not C -TB Gold ovider Phone:	resent D e	MARDS/biolog	

CONFIDENTIALITY NOTICE: The following includes confidential, proprietary information that is the sole exclusive property of KabaFusion Holdings, LLC. No rights in, relating to, or derived from such information are assigned or otherwise transferred by this document, and the recipient of such information is subject to obligations of secrecy to and for the benefit of KabaFusion Holdings, LLC. Any unauthorized use or disclosure of such information is strictly prohibited. This message, together with any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain information that is confidential and prohibited from disclosure. If you are not the intended recipient, you are hereby notified that any dissemination, or copying of this message, or any attachment, is strictly prohibited. If you have received this message in error, please notify the original sender immediately by telephone or by return fax and shred this document along with any other documents. Thank you.

Date: ___